Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment.

Company profile
Ticker
HOLX
Exchange
Website
CEO
Stephen MacMillan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Acessa Health Inc. • Beijing Hologic Technology Co., Ltd. • Benassar Diagnostica-Equipamientos Medicos Unipessoal, Lda. • BioLucent, LLC • Bioptics, Inc. • Biotheranostics, Inc. • Cytyc Corporation • Cytyc Prenatal Products Corp. • Cytyc Surgical Products, LLC • Diagenode Co., Ltd. ...
IRS number
42902449
HOLX stock data
News
Hologic Reports European CE Mark For Molecular Assay For Use With Transplant Patients
25 May 22
Expert Ratings for Hologic
17 May 22
SVB Leerink Maintains Outperform on Hologic, Raises Price Target to $85
17 May 22
CNBC's Final Trades: Charles Schwab And These 3 Medical Stocks
12 May 22
15 Stocks Moved By Traders on 'Fast Money: Halftime Report'
11 May 22
Press releases
New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options
1 Jul 22
Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree
17 May 22
Hologic Announces FDA Approval of Aptima® CMV Quant Assay for Human Cytomegalovirus
10 May 22
Hologic to Webcast Presentation at Upcoming Investor Conference
4 May 22
Hologic Announces Financial Results for Second Quarter of Fiscal 2022
27 Apr 22
Analyst ratings and price targets
Current price
Average target
$79.60
Low target
$75.00
High target
$85.00
SVB Leerink
Maintains
$85.00
Citigroup
Maintains
$75.00
Raymond James
Maintains
$83.00
Wells Fargo
Downgraded
$75.00
Evercore ISI Group
Downgraded
$80.00
Investment data
Securities sold
Number of investors
Calendar
27 Apr 22
2 Jul 22
28 Sep 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 21 | Sep 20 | Sep 19 | Sep 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 May 22 | Benjamin Jordan Cohn | Common Stock | Sell | Dispose S | No | No | 78.754 | 3,844 | 302.73K | 13,532 |
17 May 22 | Benjamin Jordan Cohn | Common Stock | Option exercise | Acquire M | No | No | 40.85 | 3,844 | 157.03K | 17,376 |
17 May 22 | Benjamin Jordan Cohn | NQSO Common Stock | Option exercise | Dispose M | No | No | 40.85 | 3,844 | 157.03K | 0 |
17 May 22 | Jan Verstreken | Common Stock | Sell | Dispose S | No | No | 78.795 | 6,500 | 512.17K | 64,191 |
13 May 22 | Benjamin Jordan Cohn | Common Stock | Sell | Dispose S | No | No | 75.49 | 3,842 | 290.03K | 13,532 |
13 May 22 | Benjamin Jordan Cohn | Common Stock | Option exercise | Acquire M | No | No | 40.85 | 3,842 | 156.95K | 17,374 |
13 May 22 | Benjamin Jordan Cohn | Common Stock | Sell | Dispose S | No | No | 75.493 | 3,210 | 242.33K | 13,532 |
13 May 22 | Benjamin Jordan Cohn | Common Stock | Option exercise | Acquire M | No | No | 37.64 | 3,210 | 120.82K | 16,742 |
13 May 22 | Benjamin Jordan Cohn | NQSO Common Stock | Option exercise | Dispose M | No | No | 40.85 | 3,842 | 156.95K | 3,844 |
13 May 22 | Benjamin Jordan Cohn | NQSO Common Stock | Option exercise | Dispose M | No | No | 37.64 | 3,210 | 120.82K | 0 |
Financial report summary
?Competition
General Electric • Medtronic • Medite Cancer Diagnostics • Koninklijke Philips • Danaher • Applied Dna Sciences • Icad • VASO • Merit Medical Systems • Viveve MedicalRisks
- The COVID-19 pandemic and associated economic disruptions have had and may continue to have a material adverse effect on manufacturing, distribution and supply chain.
- Continuing worldwide political and social uncertainty, as well as tariffs and social tensions, may adversely affect our business and prospects, both domestically and internationally.
- Our international operations and foreign acquisitions expose us to additional operational challenges that we might not otherwise face.
- Our reliance on one third-party manufacturer for certain of our product lines and a limited number of suppliers for some key raw materials, components and subassemblies for our products exposes us to increased risks associated with production delays, delivery schedules, manufacturing capability, quality control, quality assurance and costs.
- Interruptions, delays, shutdowns or damage at our manufacturing or laboratory facilities could harm our business.
- Our Diagnostics segment depends on a small number of customers for a significant portion of its product sales, and the loss of any of these customers or any cancellation or delay of a large purchase by any of these customers could significantly reduce revenues in our Diagnostics segment.
- We utilize distributors for a portion of our sales, the loss of which could harm our revenues in the territory serviced by these distributors.
- Our success depends on our ability to attract, motivate and retain key personnel and plan for future executive transitions.
- Increased cybersecurity requirements, vulnerabilities, threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, products, solutions, services and data.
- Failure to comply with laws relating to the confidentiality of sensitive personal information or standards related to the transmission of electronic health data, may require us to make significant changes to our products, or incur penalties or other liabilities.
- Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects.
- Guidelines, recommendations and studies published by various organizations may reduce the use of our products.
- Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company's operating results.
- We operate in a highly regulated industry, and changes in healthcare laws and regulations or our inability to obtain in a timely manner or at all U.S. or foreign regulatory clearances or approvals for our current and newly developed products and services or product or service enhancements, could adversely affect our business and prospects.
- Some of our activities may subject us to risks under federal and state laws prohibiting “kickbacks” and false or fraudulent claims.
- We are subject to the risk of product liability claims relating to our products for which we may not have adequate insurance.
- We are subject to environmental, health and safety laws and regulations, including related to our use and recycling of hazardous materials and the composition of our products.
- Our business is dependent on technologies we license, and if we fail to maintain these licenses or license new technologies and rights to particular nucleic acid sequences for targeted diseases in the future, we may be limited in our ability to develop new products.
- Our business could be harmed if we are unable to protect our proprietary technology.
- Our business could be harmed if we infringe upon the intellectual property rights of others.
- We may not be able to generate sufficient cash flow to service all of our indebtedness and other obligations.
- A significant portion of our indebtedness is subject to floating interest rates, which may expose us to higher interest payments.
- The proposed discontinuation or replacement of LIBOR would require us to amend certain agreements and may otherwise adversely affect our business.
- Provisions in our charter, bylaws, and indebtedness may have the effect of discouraging advantageous offers for our business or common stock and limit the price that investors might be willing to pay in the future for shares of our common stock.
- Our stock price is volatile.
Management Discussion
- All dollar amounts in tables are presented in millions.
- We had a decrease in product revenues in both the current three and six month periods of 8.0% and 9.3%, respectively, compared to the corresponding periods in the prior year. This was primarily due to the decrease in revenues in the Diagnostics business as COVID-19 assay sales were lower, and to a lesser extent, there was also a decrease in Breast Health revenue primarily due to supply chain constraints.
- Diagnostics product revenues decreased $78.7 million and $262.3 million, or 7.5% and 12.2%, respectively, in the current three and six month periods compared to the corresponding periods in the prior year primarily due to a decrease in Molecular Diagnostics of $74.3 million and $261.6 million, respectively, a decrease in Blood Screening of $2.6 million and $4.7 million, respectively, and a decrease in Cytology & Perinatal for the current three month period of $1.8 million. Cytology & Perinatal revenue increased $4.0 million in the current six month period compared to the corresponding prior year period. Molecular Diagnostics product revenue was $842.9 million and $1,637.7 million, respectively, in the current three and six month periods compared to $917.2 million and $1,899.4 million in the corresponding periods in the prior year. The decrease was primarily attributable to a decrease of $95.1 million and $317.8 million, respectively, in sales from our two SARS-CoV-2 assays due to lower volumes , which we primarily attribute to lower demand from an improvement in the COVID-19 pandemic compared to the prior year and a decrease in average selling prices. We also had a decrease in the sale of our Panther and Panther Fusion instruments in the current year periods compared to the prior year periods. These decreases were partially offset by an increase in sales of $14.6 million and $39.6 million in the current three and six month periods for our Aptima assays and STD collection kits (exclusive of our Aptima SARS-CoV-2 assays), which primarily consisted of our CTGC, Bacterial Vaginosis, and CV Candida assays, on a worldwide basis as volumes increased, partially offset by lower HPV assay volumes. In addition, we had an increase from our Quant Viral assays as well as an increase of $8.7 million and $25.0 million, respectively, in the current three and six month periods from the inclusion of our recent acquisitions of Mobidiag and Diagenode. We also experienced a decrease in revenue from the unfavorable foreign currency exchange impact of the strengthened U.S. dollar against a number of currencies.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
advertising, Bowl, carryback, certified, death, inflow, influenza, milestone, Omicron, parainfluenza, Quant, slowdown, STD, Super, syncytial, Ukraine, unvested, uptick
Removed:
added, cancelled, collateral, consulting, divested, division, eased, favorable, GBS, implement, IVDR, MDR, outflow, Pap, recover, significantly, unbenefited, Vitro
Financial reports
Current reports
8-K
Results of Operations and Financial Condition
27 Apr 22
8-K
Submission of Matters to a Vote of Security Holders
11 Mar 22
8-K
Results of Operations and Financial Condition
2 Feb 22
8-K
Results of Operations and Financial Condition
10 Jan 22
8-K
Departure of Directors or Certain Officers
4 Nov 21
8-K
Results of Operations and Financial Condition
1 Nov 21
8-K
Entry into a Material Definitive Agreement
27 Sep 21
8-K
Results of Operations and Financial Condition
28 Jul 21
8-K
Other Events
17 Jun 21
8-K
Results of Operations and Financial Condition
28 Apr 21
Registration and prospectus
S-3ASR
Automatic shelf registration
27 Nov 19
S-8
Registration of securities for employees
2 May 18
SC TO-I/A
Issuer tender offer statement (amended)
28 Feb 18
SC TO-I/A
Issuer tender offer statement (amended)
8 Feb 18
SC TO-I
Issuer tender offer statement
28 Jan 18
SC TO-I/A
Issuer tender offer statement (amended)
14 Dec 17
SC TO-I
Issuer tender offer statement
13 Nov 17
SC TO-T/A
Third party tender offer statement (amended)
21 Mar 17
SC TO-T/A
Third party tender offer statement (amended)
19 Mar 17
SC TO-T/A
Third party tender offer statement (amended)
9 Mar 17
Proxies
DEFA14A
Additional proxy soliciting materials
22 Feb 22
DEFA14A
Additional proxy soliciting materials
20 Jan 22
DEFA14A
Additional proxy soliciting materials
16 Feb 21
DEFA14A
Additional proxy soliciting materials
21 Jan 21
DEFA14A
Additional proxy soliciting materials
11 Feb 20
DEFA14A
Additional proxy soliciting materials
22 Jan 20
DEF 14A
Definitive proxy
22 Jan 20
DEFA14A
Additional proxy soliciting materials
14 Feb 19
Other
SD
Conflict minerals disclosure
27 May 22
SD
Conflict minerals disclosure
28 May 21
SD
Conflict minerals disclosure
29 May 20
SD
Conflict minerals disclosure
31 May 19
SD
Conflict minerals disclosure
31 May 18
CT ORDER
Confidential treatment order
15 Apr 18
CT ORDER
Confidential treatment order
10 Dec 17
SD
Conflict minerals disclosure
30 May 17
CT ORDER
Confidential treatment order
4 Dec 16
SD
Conflict minerals disclosure
30 May 16
Ownership
4
HOLOGIC / Jan Verstreken ownership change
19 May 22
4
HOLOGIC / BENJAMIN JORDAN COHN ownership change
19 May 22
4
HOLOGIC / BENJAMIN JORDAN COHN ownership change
17 May 22
4
HOLOGIC / BENJAMIN JORDAN COHN ownership change
4 May 22
4
HOLOGIC / Amy McBride Wendell ownership change
14 Mar 22
4
HOLOGIC / Christiana Stamoulis ownership change
14 Mar 22
4
HOLOGIC / Namal Nawana ownership change
14 Mar 22
4
HOLOGIC / Charles J Dockendorff ownership change
14 Mar 22
4
HOLOGIC / LUDWIG HANTSON ownership change
14 Mar 22
4
HOLOGIC / SCOTT T GARRETT ownership change
14 Mar 22
Patents
Utility
System and Method for Hierarchical Multi-level Feature Image Synthesis and Representation
23 Jun 22
A method for processing breast tissue image data includes processing the image data to generate a set of image slices collectively depicting the patient's breast; for each image slice, applying one or more filters associated with a plurality of multi-level feature modules, each configured to represent and recognize an assigned characteristic or feature of a high-dimensional object; generating at each multi-level feature module a feature map depicting regions of the image slice having the assigned feature; combining the feature maps generated from the plurality of multi-level feature modules into a combined image object map indicating a probability that the high-dimensional object is present at a particular location of the image slice; and creating a 2D synthesized image identifying one or more high-dimensional objects based at least in part on object maps generated for a plurality of image slices.
Utility
Fundus Bumper Mechanical Reference for Easier Mechanism Deployment
23 Jun 22
Intrauterine devices and methods for facilitating deployment thereof using a bumper are disclosed.
Utility
Marking Device and Implantation System
23 Jun 22
Marking device (100) for implantation into a tissue (260), having a support structure (102) which is formed by at least one elastic metal wire, is compressible and is self-expanding and which, in an expanded state, encompasses an interior space (104), characterized in that the marking device (100) is designed to transform itself on its own from a compressed state into an expanded state, even against a tissue pressure prevailing at a tissue site to be marked, and the marking device (100) in the expanded state has a hollow, approximately spherical shape.
Utility
Systems and methods for pivoting compression paddles
21 Jun 22
The housing for a breast imaging system contains an x-ray source and is configured to rotate relative to the breast.
Utility
System and method for navigating x-ray guided breast biopsy
21 Jun 22
A method of performing a procedure on a breast of a patient includes compressing the breast of the patient with a paddle of an imaging system and performing an initial imaging procedure on the breast of the patient.
Transcripts
2022 Q2
Earnings call transcript
28 Apr 22
2022 Q1
Earnings call transcript
3 Feb 22
2021 Q4
Earnings call transcript
2 Nov 21
2021 Q3
Earnings call transcript
29 Jul 21
2021 Q2
Earnings call transcript
29 Apr 21
2021 Q1
Earnings call transcript
28 Jan 21
2020 Q4
Earnings call transcript
4 Nov 20
2020 Q3
Earnings call transcript
29 Jul 20
2020 Q2
Earnings call transcript
29 Apr 20
2020 Q1
Earnings call transcript
29 Jan 20
Reddit threads
229 S&P500 companies ($21.6t in market cap, 61.8%) report earnings in the next ~30 days
25 Jun 22
Roe v Wade Overturned - Buy Birth Control / Contraception stocks?
24 Jun 22
Build your own ETF
24 May 22
Daily Discussion Thread - April 27th, 2022
27 Apr 22
Daily Discussion Thread - April 26th, 2022
26 Apr 22
Daily Discussion Thread - April 25th, 2022
25 Apr 22
Here's Your Daily Market Brief For April 4th
4 Apr 22
Here's Your Daily Market Brief For April 4th
4 Apr 22
Daily Discussion Thread - February 2nd, 2022
2 Feb 22
Daily Discussion Thread - February 1st, 2022
1 Feb 22